文献速递血管炎

利妥昔单抗作为ANCA相关性血管炎维持治疗:MAINRITSAN试验277例患者的汇总分析及长期结局

Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
PubMed 文献 · Ann Rheum Dis · 2024-01-11

该汇总分析纳入MAINRITSAN系列试验中277例经诱导治疗达完全缓解的ANCA相关性血管炎患者,比较硫唑嘌呤、18个月固定方案利妥昔单抗、18个月定制方案利妥昔单抗及36个月利妥昔单抗预防复发的长期疗效与安全性。主要终点为第84个月无复发生存。

要点

  • 18个月固定方案利妥昔单抗在预防重大复发方面优于硫唑嘌呤(HR 0.38,95%CI 0.20-0.71)。
  • 18个月定制方案利妥昔单抗较固定方案与重大复发风险升高相关(HR 2.92,95%CI 1.43-5.96)。
  • 36个月固定/固定方案与18个月固定方案利妥昔单抗的重大复发风险相似(HR 0.69,95%CI 0.38-1.25)。

核心结论

  • 根据这些结果,18个月固定方案利妥昔单抗的第84个月缓解率似乎高于硫唑嘌呤和18个月定制方案利妥昔单抗。
  • 此外,与18个月固定方案利妥昔单抗相比,将利妥昔单抗延长至36个月似乎并未降低长期复发率。
  • 然而,由于本研究进行该比较的检验效能不足,需要进一步的前瞻性研究来确定延长治疗在这些患者中的潜在长期获益。

研究设计与样本

  • MAINRITSAN系列试验依次比较:18个月固定方案利妥昔单抗 vs 硫唑嘌呤(MAINRITSAN);18个月固定方案利妥昔单抗 vs 18个月定制方案利妥昔单抗(MAINRITSAN2);在MAINRITSAN2后额外4次利妥昔单抗输注延长至36个月 vs 安慰剂(MAINRITSAN3)。
  • 患者随后前瞻性随访至第84个月,数据汇总分析复发和不良事件。
  • 277例患者入组,分为5组:硫唑嘌呤组(n=58)、18个月固定方案利妥昔单抗组(n=97)、18个月定制方案利妥昔单抗组(n=40)、36个月定制/固定方案利妥昔单抗组(n=42)、36个月固定/固定方案利妥昔单抗组(n=41)。
  • 主要终点为第84个月无复发生存。

主要发现

  • 经预后因素校正后,18个月固定方案利妥昔单抗在预防第84个月重大复发方面优于硫唑嘌呤(HR 0.38,95%CI 0.20-0.71)。
  • 18个月定制方案利妥昔单抗与固定方案相比,重大复发风险升高(HR 2.92,95%CI 1.43-5.96)。
  • 36个月固定/固定方案与18个月固定方案利妥昔单抗的重大复发风险相似(HR 0.69,95%CI 0.38-1.25)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 本研究进行36个月与18个月固定方案利妥昔单抗比较的检验效能不足。
  • 需要进一步的前瞻性研究来确定延长治疗在这些患者中的潜在长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achieved a complete remission after induction therapy. Patients treated with 36-month RTX received either a fixed or a tailored regimen for the first 18 months and a fixed regimen for the last 18 months (36-month fixed/fixed RTX and 36-month tailored/fixed RTX, respectively). METHODS: The Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trials sequentially compared: 18-month fixed-schedule RTX versus AZA (MAINRITSAN); 18-month fixed-schedule RTX versus 18-month tailored-RTX (MAINRITSAN2); and extended therapy to 36 months with four additional RTX infusions after MAINRITSAN2 versus placebo (MAINRITSAN3). Patients were then followed prospectively through month 84 and their data were pooled to analyse relapses and adverse events. The primary endpoint was relapse-free survival at month 84. RESULTS: 277 patients were enrolled and divided in 5 groups: AZA (n=58), 18-month fixed-schedule RTX (n=97), 18-month tailored-RTX (n=40), 36-month tailored/fixed RTX (n=42), 36-month fixed/fixed RTX (n=41). After adjustment for prognostic factors, 18-month fixed-schedule RTX was superior to AZA in preventing major relapses at month 84 (HR 0.38, 95% CI 0.20 to 0.71). The 18-month tailored-RTX regimen was associated with an increased risk of major relapse compared with fixed-schedule regimen (HR 2.92, 95% CI 1.43 to 5.96). The risk of major relapse was similar between 36-month fixed/fixed and 18-month fixed-RTX (HR 0.69, 95% CI 0.38 to 1.25). CONCLUSIONS: According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. However, as this study was underpowered to make this comparison, further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Delestre F, Charles P, Karras A, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2024. PMID: 37918894. doi:10.1136/ard-2023-224623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。